KOD Kodiak Sciences
- 3.780
- -0.200-5.03%
Kodiak Sciences News
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline Including Advancements With High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile. KSI-501 clinical and non-clinical data hig
BGC, DRS and AMTX Are Among After Hour Movers
Kodiak Sciences Is Maintained at Neutral by UBS
Kodiak Sciences Is Maintained at Neutral by UBS
UBS Maintains Neutral on Kodiak Sciences, Raises Price Target to $5
UBS analyst Eliana Merle maintains Kodiak Sciences with a Neutral and raises the price target from $3 to $5.
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million. Kineta (NASDAQ:KA) shares rose 8.46% to
Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript
Kodiak Sciences Is Maintained at Underweight by Barclays
Kodiak Sciences Is Maintained at Underweight by Barclays
Barclays Maintains Underweight on Kodiak Sciences, Raises Price Target to $3
Barclays analyst Gena Wang maintains Kodiak Sciences (NASDAQ:KOD) with a Underweight and raises the price target from $2 to $3.
Kodiak Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 -44.24% Barclays $2 → $3 Maintains Underweight 12/21/2023 -44.24% UBS $4 → $3 Maintains Neutral
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Walgreens Boots Alliance (WBA) and Kodiak Sciences (KOD)
Barclays Sticks to Their Sell Rating for Kodiak Sciences (KOD)
12 Health Care Stocks Moving In Friday's Intraday Session
GainersAvalo Therapeutics (NASDAQ:AVTX) shares increased by 364.8% to $22.08 during Friday's regular session. The market value of their outstanding shares is at $17.6 million. Nexalin Technology (NASD
Earnings Call Summary | Kodiak Sciences(KOD.US) Q4 2023 Earnings Conference
The following is a summary of the Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript:Financial Performance:No financial performance details were provided in the call.Business Progress:Kodiak
Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript
Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript
Kodiak Sciences GAAP EPS of -$1.13 Misses by $0.31
Sector Update: Health Care
Health care stocks were rising late Thursday afternoon, with the NYSE Health Care Index up 0.4% and the Health Care Select Sector SPDR Fund (XLV) adding 0.3%. The iShares Biotechnology ETF (IBB) decre
Top Midday Decliners
Urban-gro's (UGRO) price target was cut by Craig Hallum to $3.25 from $6, while its buy rating was maintained. The company's Q4 adjusted loss late Wednesday widened to $0.34 per share from $0.24 a yea
Kodiak Sciences Shares Tumble After Wider-Than-Expected Q4 Loss
Kodiak Sciences (KOD) shares tumbled 28% in recent Thursday trading after the company earlier reported a Q4 loss of $1.13 per diluted share, narrower than a loss of $1.35 a year earlier. Analysts surv
KOD, ALLG and SST Among Mid-day Movers
IBio, Mesoblast, Kodiak Sciences Among Healthcare Movers
Analysis
Price Target
No Data
